Payment overview · 2025
General Payments
$35.42
2 reported records · 1 companies
Healthcare provider profile · identity verified
Christopher Mahr, MD
Allopathic & Osteopathic Physicians|Family Medicine · MANNING, SC · NPI 1801880190
Verified facts
What the public records show
CMS Open Payments records show Christopher Mahr, MD received $35.42 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.42 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $35.42 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 874 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 151 |
| Potassium Chloride | Potassium Chloride | 311 | 70 |
| Losartan Potassium | Losartan Potassium | 287 | 68 |
| Metformin Hcl | Metformin Hcl | 285 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 53 |
| Gabapentin | Gabapentin | 271 | 73 |
| Carvedilol | Carvedilol | 264 | 58 |
| Furosemide | Furosemide | 218 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 59 |
| Lisinopril | Lisinopril | 211 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 70 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 186 | 44 |
| Januvia | Sitagliptin Phosphate | 185 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 170 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 37 |
| Eliquis | Apixaban | 151 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 39 |
| Allopurinol | Allopurinol | 144 | 37 |
| Nifedipine Er | Nifedipine | 143 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 30 |
| Valsartan | Valsartan | 121 | 33 |
| Sertraline Hcl | Sertraline Hcl | 119 | 25 |
| Spironolactone | Spironolactone | 118 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 31 |
| Ozempic | Semaglutide | 103 | 16 |
| Entresto | Sacubitril/Valsartan | 102 | 17 |
| Omeprazole | Omeprazole | 99 | 26 |
| Glipizide Er | Glipizide | 98 | 20 |
| Famotidine | Famotidine | 96 | 31 |
| Farxiga | Dapagliflozin Propanediol | 91 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 17 |
| Montelukast Sodium | Montelukast Sodium | 91 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 37 |
| Kerendia | Finerenone | 80 | 13 |
| Myrbetriq | Mirabegron | 79 | 17 |
| Xarelto | Rivaroxaban | 72 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 70 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 67 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 15 |
| Ezetimibe | Ezetimibe | 65 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 39 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 55 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 54 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | 12 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 34 |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Indapamide | Indapamide | 33 | suppressed |
| Repatha Syringe | Evolocumab | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Colchicine | Colchicine | 28 | 13 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Prednisone | Prednisone | 19 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Edarbi | Azilsartan Medoxomil | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35.42 · 2 records | ABBVIE INC. | QULIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error